DarioHealth Corp. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
DarioHealth Corp. (DRIO) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of -$15.22 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-08-11
- DarioHealth Corp. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2026-03-31 was -$6.85M, a 6272.07% decline year-over-year.
- DarioHealth Corp. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was $111.00K.
- DarioHealth Corp. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was -$1.76M.
- DarioHealth Corp. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was -$10.51M, a 153.21% decline year-over-year.
- DarioHealth Corp. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was -$5.97M.
- DarioHealth Corp. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was -$8.96M.
- DarioHealth Corp. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was -$12.67M, a 193.72% decline from fiscal 2022.
- DarioHealth Corp. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was $13.52M, a 87.21% increase from fiscal 2021.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | -$15.22M 10-Q · filed 2026-08-11 | |||||
| 2026-03-31 | -$6.85M 10-Q · filed 2026-05-13 | |||||
| 2025-12-31 | -$5.97M 10-K · filed 2026-03-19 | |||||
| 2025-09-30 | $4.16M 10-Q · filed 2025-11-13 | |||||
| 2025-06-30 | -$5.84M 10-Q · filed 2026-08-11 | |||||
| 2025-03-31 | $111.00K 10-Q · filed 2026-05-13 | |||||
| 2024-12-31 | -$8.96M 10-K · filed 2026-03-19 | |||||
| 2024-09-30 | -$20.54M 10-Q · filed 2025-11-13 | |||||
| 2024-06-30 | -$13.15M 10-Q · filed 2025-08-12 | |||||
| 2024-03-31 | -$1.76M 10-Q · filed 2025-05-14 | |||||
| 2023-12-31 | -$12.67M 10-K · filed 2025-03-10 | |||||
| 2023-09-30 | -$5.25M 10-Q · filed 2024-11-07 | |||||
| 2023-06-30 | $3.47M 10-Q · filed 2024-08-08 | |||||
| 2023-03-31 | -$10.51M 10-Q · filed 2024-05-15 | |||||
| 2022-12-31 | $13.52M 10-K · filed 2024-03-28 | |||||
| 2022-09-30 | $21.26M 10-Q · filed 2023-11-02 | |||||
| 2022-06-30 | $32.13M 10-Q · filed 2023-08-10 | |||||
| 2022-03-31 | $19.75M 10-Q · filed 2023-05-11 | |||||
| 2021-12-31 | $7.22M 10-K · filed 2023-03-09 | |||||
| 2021-09-30 | $22.80M 10-Q · filed 2022-11-14 | |||||
| 2021-06-30 | $35.34M 10-Q · filed 2022-08-15 | |||||
| 2021-03-31 | $52.64M 10-Q · filed 2022-05-12 | |||||
| 2020-12-31 | $8.19M 10-K · filed 2022-03-22 | |||||
| 2020-09-30 | $16.50M 10-Q · filed 2021-11-15 | |||||
| 2020-06-30 | -$7.23M 10-Q · filed 2021-08-16 | |||||
| 2020-03-31 | -$4.57M 10-Q · filed 2021-05-17 | |||||
| 2019-12-31 | $9.41M 10-K · filed 2021-03-09 | |||||
| 2019-09-30 | -$6.40M 10-Q · filed 2020-11-12 | -$6.41M 10-Q · filed 2019-10-28 | ||||
| 2019-06-30 | -$3.00M 10-Q · filed 2020-08-12 | -$3.01M 10-Q · filed 2019-08-13 | ||||
| 2019-03-31 | -$4.03M 10-Q · filed 2020-05-12 | |||||
| 2018-12-31 | $7.20M 10-K · filed 2020-03-17 | |||||
| 2018-09-30 | $7.71M 10-Q · filed 2019-10-28 | |||||
| 2018-06-30 | $1.29M 10-Q · filed 2019-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CVRx, Inc. (CVRX) | United States | $0.067B | -2.62 |
| FRACTYL HEALTH, INC. (GUTS) | United States | $0.075B | -1.18 |
| TELA Bio, Inc. (TELA) | United States | $0.057B | -0.82 |
| RenovoRx, Inc. (RNXT) | United States | $0.076B | -3.62 |
| Xtant Medical Holdings, Inc. (XTNT) | United States | $0.053B | |
| Spectral AI, Inc. (MDAI) | United States | $0.052B | |
| Pulmonx Corp (LUNG) | United States | $0.082B | -1.16 |
| Sensus Healthcare, Inc. (SRTS) | United States | $0.048B | -3.24 |
| SkinHealth Systems Inc. (SKIN) | United States | $0.086B | -3.17 |
| LENSAR, Inc. (LNSR) | United States | $0.087B | 2.02 |